StreetAlpha.app
Home › Stocks › ONC

BeOne Medicines Ltd. (ONC)

Healthcare
$413.26
▲ +0.48%
LAST CLOSE · NOV 17

BeOne Medicines makes prescription medicines, including BRUKINSA and TEVIMBRA, and sells them in several countries. It last closed at $413.26 on Nov 17, up 0.48% on the day. ONC last reported earnings on Wed, Aug 5, 2026. The average 12-month price target from 7 analysts is $454.00 (+9.9% from the last close), with a high of $476.00 and a low of $435.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 7 dark pool prints totaling $5.9M, the largest $1.4M.

AI Auto Pilots
Is ONC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.6B
+32.9% vs a year ago
Net income
$915.6M
+1235.6% vs a year ago
EPS (diluted)
$0.60
+1400.0% vs a year ago
Free cash flow
$1.4B
21.9% margin
Valuation
Market cap
$614B
1.48B shares
P/E
688.8
Price over 12 month EPS
Price to sales
92.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.8B
At Sep 30
Debt
$738.5M
At Sep 30
Shareholder equity
$5.8B
Shares outstanding
1.48B
At Oct 30
Employees12,000 (Sep 30, 2026)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.2B$1.2BFY2021FY2022: $1.4B$1.4BFY2022FY2023: $2.5B$2.5BFY2023FY2024: $3.8B$3.8BFY2024FY2025: $5.3B$5.3BFY2025

From ONC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Aug 5
2026 · Before the open (BMO)
Reported EPS
$2.05
vs $1.40 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±6.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on ONC in the past 90 days
Average 12-month target
$454.00
▲ 9.9% upside

Based on 7 analysts who set a price target on ONC in the past 90 days. The average target is $454.00, with a high of $476.00 and a low of $435.00, compared with the last close of $413.26.

Low $435.00Avg $454.00High $476.00
Blue marker: last close $413.26
Highest target$476.00
Average target$454.00
Lowest target$435.00
Latest rating changes
Morgan StanleyMaintained
Nov 13Buy$476
RBC CapitalTarget raised
Nov 6Buy$459 → $465
Truist SecuritiesTarget raised
Nov 6Buy$420 → $448
BarclaysTarget raised
Nov 6Buy$415 → $446
CitizensTarget raised
Nov 6Buy$405 → $463
DateFirmActionRatingPrice target
Nov 13Morgan StanleyMaintainedBuy$476
Nov 6RBC CapitalTarget raisedBuy$459 → $465
Nov 6Truist SecuritiesTarget raisedBuy$420 → $448
Nov 6BarclaysTarget raisedBuy$415 → $446
Nov 6CitizensTarget raisedBuy$405 → $463
Loading…

Technical Analysis

ONC · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 6% above its 20 day and 10% above its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot at $411.43, and the nearest resistance the Pivot R1 at $415.76.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 2.8%/day
Key levels
$424.7052 week high+2.8%
$424.70Swing high (Nov 10)+2.8%
$415.76Pivot R1+0.6%
$413.26Last close
$411.43Pivot−0.4%
$408.94Pivot S1−1.0%
$390.2420 day average−5.6%
$371.4650 day average−10.1%
$365.14Swing low (Aug 24)−11.6%
$353.24100 day average−14.5%
$328.49200 day average−20.5%
$253.9552 week low−38.5%
Indicators
RSI (14)64.44Strong, overbought above 70Neutral
MACD13.89Above its signal lineBullish
Stochastic85.7Near the top of its rangeOverbought
ADX (14)20.7Weak trend
Williams %R-14.8Oversold below −80, overbought above −20Overbought
CCI (20)70.2Oversold below −100, overbought above 100Neutral
Rate of change+16.5%Change over 10 sessionsBullish
ATR (14)$11.57Typical daily range, 2.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ONC

What happened before

See how ONC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ONC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ONC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ONC in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
7
Notional
$5.9M
Largest print
$1.4M
Loading…

ONC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲201 buying vs 101 selling
  • ●Held by funds +0.1 pts
  • ▲Funds holding +41
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding325284+14.4%
In funds' top 1065+20.0%
Held by funds2.5%2.4%+0.1 pts
New / increased71 / 13044 / 123+20.4%
Reduced / sold out72 / 2968 / 41−7.3%
Put/call ratio0.971.02−5.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ONC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONC is in one of them and how their past ONC trades turned out.

ONC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ONC in an article yet. Here's the latest on the wider market.

About BeOne Medicines

BeOne Medicines makes prescription medicines, including BRUKINSA and TEVIMBRA, and sells them in markets including the U.S., China and Europe. It is headquartered in Basel, Switzerland. Its customers include patients, hospitals and government and private health insurance payors, which set the coverage and reimbursement terms that affect how its medicines are sold.

Headquarters
Basel